In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published ...

In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported in the ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side ...

US pharma giant Pfizer has provided a reminder of the merits of mRNA-based vaccines as health leaders in the USA continue to question their safety.

Pfizer rises after a study found that the company's new mRNA flu vaccine outperforms traditional shots against predominant strains.

NEW YORK -- When the final Phase 3 data came out last November showing the mRNA vaccines made by Pfizer/BioNTech and Moderna were more than 90% effective, Dr. Anthony Fauci had no words. He texted ...